Patent ID: 8921384

Claim:
A method for the treatment of a hepatitis C infection in a host in need thereof, comprising administering an effective amount of a spiro[2.4]heptane of the following structure: wherein: R 1 is a natural or non-natural heteroaryl or heterocyclic moiety; R 2 is methyl or F; R 3 is methyl, F, Cl, N 3 , or OR 7 ; R 4 is OR 7 , H, methyl, F, Cl, or N 3 ; R 5 is H, phosphate, a stabilized phosphate prodrug, phosphoramidate, acyl, alkyl, sulfonate ester, a lipid, a phospholipid, an amino acid, a carbohydrate, a peptide, a cholesterol, or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 5 is H or mono, di, or tri-phosphate; and, R 7 is H, acyl, phosphate, sulfate, amino acid, peptide, or an oxygen-protecting group; or its pharmaceutically acceptable salt; optionally in a pharmaceutically acceptable carrier.